natgillin/translations-raw huggingface dataset:
Patients were randomised to platinum-based chemotherapy, cisplatin 80 mg/m2 intravenous infusion on day 1 and gemcitabine 1250 mg/m2 intravenous infusion on days 1 and 8 of every 3-week cycle for up to 6 cycles (CG) with placebo or CG with Avastin at a dose of 7.5 or 15 mg/kg IV infusion day 1 of every 3-week cycle.
Bolesnici su randomizirani ili u skupinu koja je primala kemoterapiju na bazi platine, i to cisplatin u dozi od 80 mg/m2 primijenjen intravenskom infuzijom 1. dana i gemcitabin u dozi od 1250 mg/m2 primijenjen intravenskom infuzijom 1. i 8. dana svakog trotjednog ciklusa u trajanju do najviše 6 ciklusa (CG) i placebo ili u skupine koje su primale CG u kombinaciji s lijekom Avastin u dozi od 7,5 ili 15 mg/kg, primijenjenim i.v. infuzijom 1. dana svakog trotjednog ciklusa.
Patients were randomised to receive Aranesp at 500 μg once every three weeks or 2.25 μg/kg once weekly.
Bolesnici su randomizirani za dobivanje 500 μg Aranespa jednom u 3 tjedna ili 2,25 μg/kg jednom tjedno.
Patients were randomised to receive either oral lapatinib 1,000 mg once daily plus trastuzumab 4 mg/kg administered as an intravenous (IV) loading dose, followed by 2 mg/kg IV weekly (N = 148), or oral lapatinib 1,500 mg once daily (N = 148).
Bolesnici su randomizirani na peroralnu primjenu lapatiniba u dozi od 1000 mg jednom dnevno u kombinaciji s intravenskom udarnom dozom trastuzumaba od 4 mg/kg, nakon čega je slijedila intravenska doza od 2 mg/kg jednom tjedno (N = 148), ili na peroralnu primjenu lapatiniba u dozi od 1500 mg jednom dnevno (N = 148).
Patients were randomised to receive either Tyverb 1250 mg once daily (continuously) plus capecitabine (2000 mg/m2/day on days 1-14 every 21 days), or to receive capecitabine alone (2500 mg/m2/day on days 1-14 every 21 days).
Bolesnici su bili randomizirani da primaju ili Tyverb 1250 mg jednom dnevno (kontinuirano) plus kapecitabin (2000 mg/m2/dan od 1. do 14. dana svakih 21 dan), ili da primaju samo kapecitabin (2500 mg/m2/dan od 1. do 14. dana svakih 21 dan).
Patients were randomised to receive first-line Portrazza at 800 mg plus chemotherapy consisting of gemcitabine at 1,250 mg/m2 and cisplatin at 75 mg/m2 (Portrazza+GC Arm), or gemcitabine-cisplatin chemotherapy alone (GC Arm).
Bolesnici su bili randomizirani u skupine koje su kao prvu liniju terapije primale lijek Portrazza u dozi od 800 mg plus kemoterapiju koja se sastojala od gemcitabina u dozi od 1250 mg/m2 i cisplatina u dozi od 75 mg/m2 (Portrazza + GC) ili samo kemoterapiju gemcitabinom i cisplatinom (GC).
Patients were randomised to receive placebo + MTX, Simponi 50 mg + MTX, Simponi 100 mg + MTX or Simponi 100 mg + placebo.
Bolesnici su bili randomizirani u skupinu koja je primala placebo i MTX, skupinu koja je primala Simponi 50 mg i MTX, skupinu koja je primala Simponi 100 mg i MTX ili skupinu koja je primala Simponi 100 mg i placebo.
Patients were randomised to receive placebo, Simponi 50 mg, or Simponi 100 mg.
Bolesnici su randomizirani u skupine koje su primale placebo, Simponi 50 mg ili Simponi 100 mg.
Patients were randomised to receive Simponi 50 mg, Simponi 100 mg or placebo administered subcutaneously every 4 weeks.
Bolesnici su randomizirani u skupinu koja je svaka 4 tjedna primala supkutanu dozu lijeka Simponi od 50 mg, 100 mg ili placebo.
Patients were randomized (1:1) to receive nintedanib 200 mg orally twice daily in combination with 75 mg/m2 of intravenous docetaxel every 21 days (n = 655) or placebo orally twice daily in combination with 75 mg/m2 of docetaxel every 21 days (n = 659).
Bolesnici su bili randomizirani (1:1) kako bi primili nintedanib 200 mg peroralno dvaput dnevno u kombinaciji s 75 mg/m2 intravenskog docetaksela svakih 21 dan (n = 655) ili placebo peroralno dvaput dnevno u kombinaciji s 75 mg/m2 docetaksela svakih 21 dan (n = 659).
Patients were randomized (1:1:1) to 1 of 3 treatment arms.
Bolesnici su bili randomizirani (1:1:1) u 1 od 3 terapijske skupine.
Patients were randomized 1:1 to receive placebo + trastuzumab + docetaxel or Perjeta + trastuzumab + docetaxel.
Bolesnici su randomizirani u omjeru 1:1 u skupinu koja je primala placebo + trastuzumab + docetaksel ili u skupinu koja je primala lijek Perjeta + trastuzumab + docetaksel.
Patients were randomized 1:1 to receive Tarceva 150 mg daily or up to 4 cycles of platinum based doublet chemotherapy.
Bolesnici su randomizirani u omjeru 1:1 da primaju ili lijek Tarceva u dozi od 150 mg na dan, ili 4 ciklusa dvostruke kemoterapije na bazi platine.
Patients were randomized 1:1 to receive Tarceva 150 mg or placebo orally once daily until disease progression.
Randomizacijom u omjeru 1:1 bolesnici su primali lijek Tarceva od 150 mg ili placebo, peroralno, jednom dnevno do progresije bolesti.
Patients were randomized 2:1 to the lenalidomide or the control arm.
Bolesnici su bili randomizirani u omjeru 2:1 u skupinu koja je primala lenalidomid ili u kontrolnu skupinu.
Patients were randomized in a 1:1 fashion to treatment with either bosutinib 500 mg once daily or imatinib 400 mg once daily.
Bolesnici su randomizirani na način 1:1 za liječenje ili bosutinibom 500 mg jedanput dnevno ili imatinibom 400 mg jedanput dnevno.
Patients were randomized in a 1:1:1 ratio and received ataluren or placebo 3 times per day (morning, midday, and evening) for 48 weeks, with 57 receiving placebo, 57 receiving ataluren 10-, 10-, 20-mg/kg, and 60 receiving ataluren 20-, 20-, 40 mg/kg;
Bolesnici su randomizirani u omjeru 1:1:1 i primali su ataluren ili placebo 3 puta dnevno (ujutro, u podne i navečer) tijekom 48 tjedana, pri čemu je 57 bolesnika primalo placebo, 57 je primalo ataluren u dozi od 10-, 10-, 20-mg/kg, a 60 je primalo ataluren u dozi od 20-, 20-, 40 mg/kg.
Patients were randomized in a 1:1:1 ratio to one of 3 treatment arms.
Bolesnici su randomizirani u omjeru 1:1:1 u jednu od 3 terapijske skupine.
Patients were randomized in a 2:1 ratio and received 20 mg/kg Myozyme (n=60) or placebo (n=30) once every two weeks for 78 weeks (18 months).
Bolesnici su randomizirani u omjeru 2:1 u skupine koje su primale 20 mg/kg lijeka Myozyme (n=60) ili placebo (n=30) jedanput svaka dva tjedna tijekom 78 tjedana (18 mjeseci).
Patients were randomized to clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years.
Bolesnici su randomizirani u skupine koje su dnevno primale 75 mg klopidogrela ili 325 mg acetilsalicilatne kiseline na dan te su praćeni od 1 do 3 godine.
Patients were randomized to one of the three following treatment groups: telmisartan 80 mg (n = 8542), ramipril 10 mg (n = 8576), or the combination of telmisartan 80 mg plus ramipril 10 mg (n = 8502), and followed for a mean observation time of 4.5 years.
Bolesnici su randomizirani u jednu od sljedećih triju ispitivanih skupina: telmisartan 80 mg (n = 8542), ramipril 10 mg (n = 8576), ili kombinacija telmisartana 80 mg plus ramipril 10 mg (n = 8502), te su bili praćeni u prosječnom trajanju promatranja od 4.5 godina.
Patients were randomized to one of three double-blind treatment groups to receive saxagliptin 5 mg and dapagliflozin 10 mg added to metformin, saxagliptin 5 mg and placebo added to metformin, or dapagliflozin 10 mg and placebo added to metformin.
Bolesnici su bili randomizirani u jednu od tri skupine koje su primale dvostruko slijepo liječenje: saksagliptin u dozi od 5 mg i dapagliflozin u dozi od 10 mg kao dodatak metforminu, saksagliptin u dozi od 5 mg i placebo kao dodatak metforminu ili dapagliflozin u dozi od 10 mg plus placebo kao dodatak metforminu.
Patients were randomized to placebo or sildenafil (20 mg three times a day) in combination with bosentan (62.5-125 mg twice a day).
Bolesnici su randomizirani u skupine ili sa sildenafilom (20 mg tri puta na dan) u kombinaciji s bosentanom (62,5-125 mg dva puta na dan).
Patients were randomized to receive a subcutaneous maintenance regimen of either 90 mg ustekinumab every 8 weeks, 90 mg ustekinumab every 12 weeks or placebo for 44 weeks (for recommended maintenance posology, see section 4.2 of the STELARA Solution for injection (vial) and Solution for injection in pre filled syringe SmPC).
Bolesnici su bili randomizirani u skupine koje su primale supkutani režim održavanja od bilo 90 mg ustekinumaba svakih 8 tjedana, 90 mg ustekinumaba svakih 12 tjedana ili placebo tijekom 44 tjedna (za preproučeno doziranje održavanja, vidjeti dio 4.2 sažetka opisa svojstava lijeka STELARA otopine za injekciju (bočica) i otopine za injekciju u napunjenoj štrcaljki).
Patients were randomized to receive a subcutaneous maintenance regimen of either 90 mg ustekinumab every 8 weeks, 90 mg ustekinumab every 12 weeks or placebo for 44 weeks (for recommended maintenance posology, see section 4.2).
Bolesnici su bili randomizirani u skupine koje su primale supkutani režim održavanja od bilo 90 mg ustekinumaba svakih 8 tjedana, 90 mg ustekinumaba svakih 12 tjedana ili placebo tijekom 44 tjedna (za preproučeno doziranje održavanja, vidjeti dio 4.2).
Patients were randomized to receive either PegIntron (1.5 µg/kg/week) plus ribavirin (800 mg/day) or interferon alfa-2b (3 MIU TIW) plus ribavirin (800 mg/day) for
Bolesnici su bili randomizirani u skupine koje su primale PegIntron (1,5 μg/kg na tjedan) i ribavirin (800 mg na dan) ili interferon alfa-2b (3 mil.
Patients were randomized to receive either ribavirin (800 mg/day) plus peginterferon alfa-2b (1.5 µg/kg/week) or ribavirin (800 mg/day) plus interferon alfa-2b (3 MIU TIW) for 48 weeks with a follow-up period of 6 months.
Bolesnici su randomizirani da primaju ili ribavirin (800 mg/dan) s peginterferonom alfa-2b (1,5 μg/kg na tjedan) ili ribavirin (800 mg/dan) s interferonom alfa-2b (3 MIU triput na tjedan) tijekom 48 tjedana, uz razdoblje naknadnog praćenja koje je trajalo 6 mjeseci.
Patients were randomized to receive either ViraferonPeg (1.5 µg/kg/week) plus ribavirin (800 mg/day) or interferon alfa-2b (3 MIU TIW) plus ribavirin (800 mg/day) for
Bolesnici su bili randomizirani u skupine koje su primale ViraferonPeg (1,5 μg/kg na tjedan) i ribavirin (800 mg na dan) ili interferon alfa-2b (3 mil.
Patients were randomly assigned to placebo or Simponi 50 mg administered subcutaneously every 4 weeks.
Bolesnici su randomizirani u skupinu koja je svaka 4 tjedna primala supkutanu dozu lijeka Simponi od 50 mg, 100 mg ili placebo.
Patients were randomly assigned to placebo, Simponi 50 mg and Simponi 100 mg and were allowed to continue concomitant DMARD therapy (MTX, SSZ and/or HCQ).
Bila je dopuštena istodobna primjena stabilnih doza peroralnih aminosalicilata, kortikosteroida i/ili imunomodulatora.
Patients were randomly assigned to placebo, Simponi 50 mg, or Simponi 100 mg.
Bolesnici su nasumce podijeljeni u skupine koje su primale placebo, Simponi 50 mg ili Simponi 100 mg.
Patients were randomly assigned to receive pembrolizumab at a dose of mg/kg every 3 weeks or 10 mg/kg every 3 weeks.
Bolesnicima je nasumično dodijeljena terapija pembrolizumabom u dozi od 2 mg/kg svaka 3 tjedna ili 10 mg/kg svaka 3 tjedna.
Patients were required to have a baseline HIV-1 RNA concentration of at least 1500 copies/ml, were stratified by age (2 to < 6 years, 6 to < 12 years and 12 to 18 years) and randomized to receive one of two tipranavir with ritonavir dose regimens: 375 mg/m2/150 mg/m2 dose, compared to the 290 mg/m2/115 mg/m2 dose, plus background therapy of at least two non- protease inhibitor antiretroviral medicinal products, optimized using baseline genotypic resistance testing.
Morali su imati početnu vrijednost HIV-1 RNA najmanje 1 500 kopija/ml, stratificirani su po dobi (od 2 do < 6 godina, od 6 do < 12 godina, te od 12 do 18 godina) i randomizirani na jedan od dvaju režima tipranavira s ritonavirom: doza od 375 mg/m2/150 mg/m2 ili 290 mg/m2/115 mg/m2, plus osnovna terapija s najmanje dva neproteazna antiretrovirusna lijeka, koji su bili optimizirani pomoću početnog testiranja genotipske rezistencije.
Patients were required to have a baseline HIV-1 RNA concentration of at least 1500 copies/ml, were stratified by age (2 to < 6 years, 6 to < 12 years and 12 to 18 years) and randomized to receive one of two tipranavir with ritonavir dose regimens: 375 mg/m2/150 mg/m2 dose, compared to the 290 mg/m2/115 mg/m2 dose, plus background therapy of at least two non- protease inhibitor antiretroviral medicinal products, optimized using baseline genotypic resistance testing.
Morali su imati početnu vrijednost HIV-1 RNA najmanje 1500 kopija/ml, stratificirani su po dobi (od 2 do < 6 godina, od 6 do < 12 godina, te od 12 do 18 godina) i randomizirani na jedan od dvaju režima tipranavira s ritonavirom: doza od 375 mg/m2/150 mg/m2 ili 290 mg/m2/115 mg/m2, plus osnovna terapija s najmanje dva neproteazna antiretrovirusna lijeka, koji su bili optimizirani pomoću početnog testiranja genotipske rezistencije.
Patients were required to have documented progression, based on RECIST, within the prior 12 months and were randomized (1:1) to receive either 37.5 mg sunitinib once daily without a scheduled rest period (n = 86) or placebo (n = 85).
Bolesnici su morali imati dokumentiranu progresiju bolesti temeljem RECIST kriterija u prethodnih 12 mjeseci te su randomizirani (1:1) da primaju ili 37,5 mg sunitiniba jedanput na dan bez predviđenog razdoblja odmora (n = 86) ili placebo (n = 85).
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
Da bi bili uključeni u ispitivanje, bolesnici su morali imati promjene EKG-a sukladne s novom ishemijom ili razine srčanih enzima ili troponima I ili T najmanje dvostruko više od normalnih.
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
Kriteriji za uključivanje u studiju bili su promjene u EKG-u povezane s novom ishemijom ili povećane vrijednosti srčanih enzima, ili troponin I ili T barem dva puta veći od gornje granice normalnih vrijednosti.
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
Uključujući kriteriji bili su promjene u EKG-u povezane s novom ishemijom ili povećane vrijednosti srčanih enzima, ili troponin I ili T barem dva puta veći od gornje granice normalnih vrijednosti.
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
Uključujući kriteriji su bili promjene u EKG-u povezane s novom ishemijom ili povećane vrijednosti srčanih enzima, ili troponin I ili T barem dva puta veći od gornje granice normalnih vrijednosti.
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
Uključujći kriteriji su bili promjene u EKG-u povezane s novom ishemijom ili povećane vrijednosti srčanih enzima, ili troponin I ili T barem dva puta veći od gornje granice normalnih vrijednosti.
Patients were required to have histologically or cytologically confirmed, advanced soft tissue sarcoma and ECOG performance status of 0-2.
Bolesnici su morali imati histološki ili citološki potvrđen uznapredovali sarkom mekog tkiva i funkcionalni ECOG status 0 – 2.
Patients were required to have received adequate previous treatment with at least one prior combination chemotherapy regimen.
Uvjet je bio da su bolesnici prije bili odgovarajuće liječeni najmanje jednim prethodnim kombiniranim kemoterapijskim režimom.
Patients were stratified according to region, iNHL subtype (follicular versus non-follicular), rituximab-refractory type (whether refractory to prior rituximab monotherapy or rituximab in combination with chemotherapy) and the number of prior therapies (≤2 versus >2).
Bolesnici su bili stratificirani prema regiji, podtipu iNHL-a (folikularni ili nefolikularni), tipu refraktornosti na rituksimab (je li bolest bila refraktorna na prethodno liječenje rituksimabom u monoterapiji ili u kombinaciji s kemoterapijom) te broju prethodnih terapija (≤ 2 naspram > 2).
Patients were stratified according to their baseline haemoglobin (≤ 10 g/dl, > 10 to ≤ 13 g/dl and
Bolesnici su podijeljeni u skupine prema početnoj razini hemoglobina (≤ 10 g/dl, > 10 do
Patients were stratified at randomization by age (≤75 versus >75 years), stage (ISS Stages I and II versus Stage III), and country.
Prilikom randomizacije, bolesnici su bili stratificirani prema dobi (≤ 75 naspram > 75 godina), stadiju bolesti (ISS stadij I i II naspram stadij III) te zemlji.
Patients were stratified by baseline HIV-1 RNA and CD4 count.
Pacijenti su bili stratificirani prema početnoj vrijednosti HIV-1 RNK i broju CD4 stanica.
Patients were stratified by hemoglobin level (≤13 g/dL vs. >13 g/dL for males and ≤11.5 g/dL vs >11.5 g/dL for females) and corrected serum calcium (≥10 mg/dL vs. <10 mg/dL).
Stratificirani su prema razini hemoglobina (≤13 g/dl naspram >13 g/dl za muškarce i ≤11,5 g/dl naspram >11,5 g/dl za žene) i korigiranom kalciju u serumu (≥10 mg/dl naspram <10 mg/dl).
Patients were stratified by the class of the third agent in their prior treatment regimen.
Bolesnici su bili stratificirani ovisno o skupini trećeg lijeka u njihovom prethodnom reţimu liječenja.
Patients were studied for 3 years, and could be given repeat treatment if considered appropriate.
Bolesnici su proučavani tijekom 3 godine i mogli bi primati ponovljeno liječenje ako se to smatra prikladnim.
Patients were switched from efavirenz/emtricitabine/tenofovir disoproxil to Eviplera without a washout period.
Pacijenti su bili prebačeni s efavirenza/emtricitabina/tenofovirdizoproksila na Evipleru bez razdoblja ispiranja prethodno uzimanih lijekova.
Patients were switched without a washout period.
Bolesnici su prebacivani bez perioda ispiranja lijeka.
Patients were treated at doses of Glivec of 260 mg/m2/day (n=5), 340 mg/m2/day (n=9), 440 mg/m2/day (n=7) and 570 mg/m2/day (n=5).
Bolesnici su liječeni dozama Gliveca od 260 mg/m2/dan (n=5), 340 mg/m2/dan (n=9), 440 mg/m2/dan (n=7), te 570 mg/m2/dan (n=5).
Patients were treated at doses of imatinib of 260 mg/m2/day (n = 5), 340 mg/m2/day (n = 9), 440 mg/m2/day (n = 7) and 570 mg/m2/day (n = 5).
Bolesnici su liječeni dozama imatiniba od 260 mg/m²/dan (n=5), 340 mg/m²/dan (n=9), 440 mg/m²/dan (n=7), te 570 mg/m²/dan (n=5).
Patients were treated at doses of imatinib of 260 mg/m2/day (n=5), 340 mg/m2/day (n=9), 440 mg/m2/day (n=7) and 570 mg/m2/day (n=5).
Bolesnici su liječeni dozama imatinibaod 260 mg/m2/dan (n=5), 340 mg/m2/dan (n=9), 440 mg/m2/dan (n=7), te 570 mg/m2/dan (n=5).
Patients were treated in hospital until clinical stabilisation, revascularisation or discharge.
Bolesnici su liječeni hospitalno sve do stabilizacije kliničke slike, revaskularizacije ili otpusta.
Patients were treated with Glivec
Bolesnici su liječeni s
Patients were treated with oral daily dosing of Erivedge at 150mg.
Bolesnici su liječeni lijekom Erivedge u peroralnoj dozi od 150 mg na dan.
Patients were treated with ranibizumab 0.5 mg pro re nata (PRN) in the same eye as the core study (D2301 RESTORE).
Bolesnici su bili liječeni ranibizumabom 0,5 mg prema potrebi (p.p.) u isto oko kao u glavnom ispitivanju (RESTORE).
Patients were treated with Signifor at either 0.6 mg twice a day or 0.9 mg twice a day.
Bolesnici su liječeni lijekom Signifor dva puta na dan dozom od 0,6 mg ili dva puta na dan dozom od 0,9 mg.
Patients who accidentally received too much Thyrogen have reported nausea, weakness, dizziness, headache, vomiting and hot flashes.
Bolesnici koji su slučajno primili previše lijeka Thyrogen prijavili su mučninu, slabost, omaglicu, glavobolju, povraćanje i navale vrućine.
Patients who achieved a clinical response after receiving vedolizumab at Week 0 and 2 and were then randomised to placebo (for 6 to 52 weeks) and lost response were allowed to enter the open-label extension study and receive vedolizumab every four weeks.
Bolesnici koji su postigli klinički odgovor nakon primanja vedolizumaba u nultom i drugom tjednu i potom su randomizirani u skupinu koja je primala placebo (od 6. do 52. tjedna) te su izgubili odgovor na liječenje, mogli su ući u otvoreni nastavak ispitivanja i primati vedolizumab svaka četiri tjedna.
Patients who achieved a clinical response after receiving vedolizumab at Week 0 and 2 and were then randomised to placebo (for 6 to 52 weeks) and lost response were allowed to enter the open-label extension study and receive vedolizumab every four weeks.
Bolesnici koji su postigli klinički odgovor nakon primanja vedolizumaba u nultom i drugom tjednu te su potom randomizirani u skupinu koja je primala placebo (od 6. do 52. tjedna) te su izgubili odgovor na liječenje, mogli su ući u otvoreni nastavak ispitivanja i primati vedolizumab svaka četiri tjedna.
Patients who achieved PASI-75 at Week 32
Bolesnici koji su postigli rezultat PASI-75 u 32. tjednu
Patients who are adequately treated with 1-monthly paliperidone palmitate injectable (preferably for four months or more) and do not require dose adjustment may be switched to TREVICTA.
Na lijek TREVICTA mogu prijeći bolesnici koji su odgovarajuće liječeni paliperidonpalmitatom u obliku 1-mjesečne injekcije (poželjno kroz četiri ili više mjeseci), te ne zahtijevaju prilagodbu doze.
Patients who are allergic to peanut or soya must not take these tablets.
Ove tablete ne smiju uzimati bolesnici alergični na kikiriki ili soju.
Patients who are already on immediate-release tablets or oral suspension can switch to prolonged- release tablets without lead-in period.
Bolesnici koji su već na tabletama s trenutnim oslobađanjem ili oralnoj suspenziji mogu se prebaciti na tablete s produljenim oslobađanjem bez uvodnog razdoblja.
Patients who are at risk of infection because they do not have sufficient antibodies (proteins naturally found in the blood that help the body to fight infections and other diseases).
U bolesnika koji su izloženi riziku od infekcije jer nemaju dovoljno protutijela (bjelančevine koje se prirodno nalaze u krvi i pomažu tijelu u borbi protiv infekcija i drugih bolesti).
Patients who are being treated with chemotherapy that is moderately or highly capable of triggering nausea and vomiting may still experience vomiting despite treatment with appropriate therapy, including SANCUSO.
U bolesnika koji primaju umjereno ili izrazito emetogenu kemoterapiju mučnina i povraćanje mogu se javiti unatoč primjeni lijekova protiv mučnine i povraćanja, uključujući SANCUSO.
Patients who are blind or have poor vision must be instructed always to get help/assistance from another person who has good vision and is trained in using the insulin device;
Bolesnicima koji su slijepi ili slabo vide mora se objasniti da uvijek zatraže pomoć osobe koja dobro vidi i koja je naučila kako koristiti inzulinsko pomagalo;
Patients who are blind or have poor vision, must be instructed to always get help/assistance from another person who has good vision and is trained in using the insulin device.
Bolesnicima koji su slijepi ili slabovidni mora se objasniti da uvijek zatraže pomoć druge osobe koja ima dobar vid i koja je naučila koristiti inzulinsko pomagalo.
Patients who are concerned about their fertility while taking Glivec are advised to consult with their doctor.
Bolesnicima koji su zabrinuti za svoju plodnost tijekom uzimanja Gliveca se preporučuje da se posavjetuju sa svojim liječnikom.
Patients who are concerned about their fertility while taking Imatinib Accord are advised to consult with their doctor.
Bolesnicima koji su zabrinuti za svoju plodnost tijekom uzimanja Imatinib Accorda se preporučuje da se posavjetuju sa svojim liječnikom.
Patients who are concerned about their fertility while taking Imatinib Actavis are advised to consult with their doctor.
Bolesnicima koji su zabrinuti za svoju plodnost tijekom uzimanja Imatinib Actavisa preporučuje se da se posavjetuju sa svojim liječnikom.
Patients who are concerned about their fertility while taking Imatinib medac are advised to consult with their doctor.
Bolesnicima koji su zabrinuti za svoju plodnost tijekom uzimanja Imatinib medaca preporučuje se da se posavjetuju sa svojim liječnikom.